310 related articles for article (PubMed ID: 35203272)
21. Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism.
Latruffe N; Vamecq J
Biochimie; 1997; 79(2-3):81-94. PubMed ID: 9209701
[TBL] [Abstract][Full Text] [Related]
22. PPAR dual agonists: are they opening Pandora's Box?
Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
[TBL] [Abstract][Full Text] [Related]
23. Peroxisome proliferator-activated receptor gamma: promising target in glioblastoma.
Gupta G; Singhvi G; Chellappan DK; Sharma S; Mishra A; Dahiya R; de Jesus Andreoli Pinto T; Dua K
Panminerva Med; 2018 Sep; 60(3):109-116. PubMed ID: 30176701
[TBL] [Abstract][Full Text] [Related]
24. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
Panunti B; Fonseca V
Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
[TBL] [Abstract][Full Text] [Related]
25. PPAR Ligands Containing Stilbene Scaffold.
Fantacuzzi M; De Filippis B; Amoroso R; Giampietro L
Mini Rev Med Chem; 2019; 19(19):1599-1610. PubMed ID: 31161987
[TBL] [Abstract][Full Text] [Related]
26. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
Gani OA
Cardiovasc Diabetol; 2008 Mar; 7():6. PubMed ID: 18355413
[TBL] [Abstract][Full Text] [Related]
27. Peroxisome proliferator-activated receptors and cardiovascular remodeling.
Schiffrin EL
Am J Physiol Heart Circ Physiol; 2005 Mar; 288(3):H1037-43. PubMed ID: 15374828
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cells: thiazolidinediones are partial PPAR gamma agonists.
Chana RS; Lewington AJ; Brunskill NJ
Kidney Int; 2004 Jun; 65(6):2081-90. PubMed ID: 15149321
[TBL] [Abstract][Full Text] [Related]
29. Advances in PPARs Molecular Dynamics and Glitazones as a Repurposing Therapeutic Strategy through Mitochondrial Redox Dynamics against Neurodegeneration.
Durai P; Beeraka NM; Ramachandrappa HVP; Krishnan P; Gudur P; Raghavendra NM; Ravanappa PKB
Curr Neuropharmacol; 2022; 20(5):893-915. PubMed ID: 34751120
[TBL] [Abstract][Full Text] [Related]
30. PPARs and the cardiovascular system.
Hamblin M; Chang L; Fan Y; Zhang J; Chen YE
Antioxid Redox Signal; 2009 Jun; 11(6):1415-52. PubMed ID: 19061437
[TBL] [Abstract][Full Text] [Related]
31. Peroxisome proliferator-activated receptors, orphans with ligands and functions.
Schoonjans K; Martin G; Staels B; Auwerx J
Curr Opin Lipidol; 1997 Jun; 8(3):159-66. PubMed ID: 9211064
[TBL] [Abstract][Full Text] [Related]
32. [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].
Alemán G; Torres N; Tovar AR
Rev Invest Clin; 2004; 56(3):351-67. PubMed ID: 15612519
[TBL] [Abstract][Full Text] [Related]
33. Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma.
Zieleniak A; Wójcik M; Woźniak LA
Arch Immunol Ther Exp (Warsz); 2008; 56(5):331-45. PubMed ID: 18836859
[TBL] [Abstract][Full Text] [Related]
34. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.
Guan Y; Breyer MD
Kidney Int; 2001 Jul; 60(1):14-30. PubMed ID: 11422732
[TBL] [Abstract][Full Text] [Related]
35. The mechanisms of action of PPARs.
Berger J; Moller DE
Annu Rev Med; 2002; 53():409-35. PubMed ID: 11818483
[TBL] [Abstract][Full Text] [Related]
36. Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects.
Auwerx J; Schoonjans K; Fruchart JC; Staels B
J Atheroscler Thromb; 1996; 3(2):81-9. PubMed ID: 9226459
[TBL] [Abstract][Full Text] [Related]
37. Ligands of the peroxisome proliferator-activated receptor-gamma and heart failure.
Thiemermann C
Br J Pharmacol; 2004 Jan; 141(1):1-3. PubMed ID: 14662733
[TBL] [Abstract][Full Text] [Related]
38. Recent Insights on the Role of PPAR-β/δ in Neuroinflammation and Neurodegeneration, and Its Potential Target for Therapy.
Strosznajder AK; Wójtowicz S; Jeżyna MJ; Sun GY; Strosznajder JB
Neuromolecular Med; 2021 Mar; 23(1):86-98. PubMed ID: 33210212
[TBL] [Abstract][Full Text] [Related]
39. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.
Han L; Shen WJ; Bittner S; Kraemer FB; Azhar S
Future Cardiol; 2017 May; 13(3):279-296. PubMed ID: 28581362
[TBL] [Abstract][Full Text] [Related]
40. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
Yumuk VD
Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
